Biodesix

company

About

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$40.30M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical
Founded date
Jan 1, 2005
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:BDSX
Legal Name
Biodesix, Inc.

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring, and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
22
$462.26M
Biodesix has raised a total of $462.26M in funding over 2 rounds. Their latest funding was raised on Nov 17, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 17, 2022 Post-IPO Equity $40.30M Detail
Nov 16, 2022 Post-IPO Debt $50M 1 Perceptive Advisors Detail
Apr 7, 2022 Post-IPO Equity $11.70M Detail
Mar 7, 2022 Post-IPO Equity $50M 1 Lincoln Park Capital Fund Detail
Mar 23, 2021 Post-IPO Debt $30M Detail

Investments

Number of Investments
Number of Lead Investments
2
0
Biodesix has made 2 investments. Their most recent investment was on Nov 30, 2022, when Vetic raised ₹300M.
Date Company Name
Round Money Raised Industry Lead Investor
Nov 30, 2022 Vetic
Seed ₹300M Health Care
Nov 10, 2021 Prodo
Pre-seed $400K Manufacturing

Investors

Number of Lead Investors
Number of Investors
2
3
Biodesix is funded by 3 investors. Perceptive Advisors and Lincoln Park Capital Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Perceptive Advisors Yes Post-IPO Debt
Lincoln Park Capital Fund Yes Post-IPO Equity
CRG Debt Financing

Employee Profiles

Number of Employee Profiles
15
Biodesix has 15 current employee profiles, including Board member Matthew W. Strobeck
Board member
Board member
Board member
Executive

Acquisition

Biodesix has acquired 2 organizations. Their most recent acquisition was Integrated Diagnostics on Jul 9, 2018. They acquired Integrated Diagnostics for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition Detail
Jun 28, 2019 Oncimmune
Biotechnology acquisition Detail